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NEUROPSYCHOPHARMACOLOGICAL INVESTIGATIONS OF MDMA/COCAINE
COMBINATIONS
John J. Panos, M.A.
Western Michigan Univeristy, 2007

Despite the popularity of polydrug abuse among recreational MDMA users, relatively
few controlled experimental studies have documented the neurobehavioral effects of
MDMA in combination with other abused substances. In this study, the neurochemical
and behavioral effects of MDMA/cocaine combinations were assessed using in vivo
microdialysis with simultaneous measurement of locomotor activity (LMA). Rats were
administered cocaine (10 mg/kg or 20 mg/kg, IP), MDMA (1.5 mg/kg or 3.0 mg/kg, IP)
or combinations of cocaine and MDMA during microdialysis experiments. Microdialysis
samples were collected every 30 min for three hours prior to drug injections. Following
drug administration, six additional 30 min samples were collected over a three-hour
period. Samples were analyzed by HPLC with electrochemical detection. Locomotor
activity was monitored in microdialysis chambers equipped with infrared emitters and
detectors. The results of this study suggest the possibility that MDMA and cocaine
produce additive or synergistic neurochemical and behavioral effects. This preclinical
study may have important clinical implications and may help explain the common
practice of polydrug use among MDMA users.
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INTRODUCTION

Background Statement
Despite increased public awareness regarding the health risks of substance abuse,
recreational drug use and abuse continues to be a major problem, especially among adolescents
and young adults. The increased accessibility of "club drugs" to young adults is a growing
problem in our society. In club settings, known as "raves", the use of multiple drugs in
combination is very common. In particular, MDMA ("Ecstasy") is commonly used in
combination with other drugs, such as cocaine. Unfortunately, relatively little experimental
research exists on the neurobehavioral consequences of these drug combinations. A review of
the electronic literature databases revealed a significant gap in the literature with respect
to animal models ofpolydrug abuse that correspond to human drug abuse patterns. A
recent article by (Cowan et al., 2003) that examined MDMA use and polydrug use in
humans stressed a need for animal studies on the effects ofMDMA and combined
polydrug administration. Therefore, the aim ofthe proposed study is to examine the
neurobehavioral effects ofMDMA in combination with cocaine, and to determine the
extent to which these effects differ from those ofeither drug alone. This study may lead
to a greater understanding ofthe neurobehavioral consequences ofpolydrug abuse.

Polydrug Use
Polydrug use has become a rampant problem in modem society (Barret,
Darredeau, & Pihl, 2006; Gouzoulis-Mayfrank & Daumann, 2006; Montgomery, Fisk,
Newcombe, & Murphy, 2005; Wish, Fitzelle, O'Grady, Hsu, & Arria, 2006). Ecstasy or
3, 4-methylenedoxyamphetamne (MDMA) has the potential ofbeing a "gateway" drug
initiating further exploration with illicit substances. Wish et al (2006) conducted a self
report based study on college students; their results infer that MDMA users are more
1

likely to have used cocaine, heroin, LSD, other hallucinogens, and inhalants. In relation
to psychostimulant use, MDMA preceded cocaine use in 46% ofthe individuals surveyed
(Wish, Fitzelle, O'Grady, Hsu, & Arria, 2006).
The medical complications ofMDMA and cocaine use are documented and
include cerebral oedema and hepatic liver failure (Kramer et al., 2003). Polydrug use of
psychostimulants such as cocaine and MDMA may present several other possible
complications for the user which include high abuse potential, neurotoxic effects on the
dopaminergic and serotinegic systems, and the possibility of experiencing an
amphetamine-type psychosis. The hypothesized neurotoxic damage may impact on
cognitive and motor system function. There exists a possibility that this neurotoxic effect
could result after a single exposure to a high dose ofMDMA or even to a lower dose if
taken in combination with another psychostimulant drug. It is hypothesized that these
negative effects may result from excessive neurotransmitter release elicited by an
additive or synergistic effect ofsimultaneous polysubstance use (SPU).
A review ofthe current literature has found relatively few studies that examine
SPU (N = 19). Several researchers have called for further investigations ofpolysubstance
use including human (Barret, Darredeau, & Pihl, 2006; Gouzoulis-Mayfrank &
Daumann, 2006; Wish, Fitzelle, O'Grady, Hsu, & Arria, 2006) and animal studies
(Gouzoulis-Mayfrank & Daumann, 2006).
Polydrug use among MDMA users is common, especially MDMA use in
combination with psychostimulant drugs, such as amphetamine, methamphetamine, or
cocaine (Khorana, Pullagurla, Young, & Glennon, 2004; Riley, James, Gregory, Dingle,
& Cadger, 2001; Williams, Dratcu, Taylor, Roberts, & Oyefeso, 1998; Winstock,
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Griffiths, & Stewart, 2001). Presumably, users take other psychostimulants in
combination with MDMA to prolong or enhance its euphoric effects. Scholey et al.,
(2004) reported significantly greater psychoactive drug use among experienced MDMA
users compared to nonusers based on an internet survey. Specifically, survey data
revealed that cocaine use was greatest among heavy Ecstasy users (81%) compared to
novice (44%) and moderate (61%) MDMA users. Lua, Lin, Tseng, Hu, and Yeh (2003)
investigated polydrug abuse with MDMA in Taiwan. These investigators analyzed urine
samples from police detainees and found evidence for a high rate ofMDMA use in
combination with other illicit drugs. Despite the apparent prevalence ofpolydrug abuse
among MDMA users, only a few controlled experimental studies have documented the
neurobehavioral effects ofMDMA in combination with other drugs.

MDMA
3,4-Methylenedioxymethamphetamine (MDMA) is a ring substituted
phenylisopropylamine, and a structural analog to amphetamine. Also known as "Ecstasy"
on the street, MDMA is commonly used as a recreational drug among young adults.
Originally documented in Merck's laboratory records, MDMA was referred to as
"Methylsafrylamin" (Bemschneider-Reif, Oxler, & Freudenmann, 2006; Freudenmann,
Oxler, & Bemschneider-Reif, 2006), patented by Merck in 1912 under its chemical
structure as an intermediate product in the development ofa vasoconstrictive drug
(Bemschneider-Reif, Oxler, & Freudenmann, 2006; Freudenmann, Oxler, &
Bemschneider-Reif, 2006; Pentney, 2001). During the 1970's, MDMA was used as an
adjunct to psychotherapy (Greer & Tolbert, 1986; Meehan, Gordon, & Schechter, 1995),
reportedly to enhance communication and "self-examination". A psychotherapy study
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reported that subjective effects ofMDMA include altered states ofconsciousness with
emotional components such as empathy, acceptance, and insight (Kemmerling, Haller, &
Hinterhuber, 1996). In the early 1980's, MDMA became a popular recreational drug and
was sold legally, typically through mail order (Eisner, 1989; Ray & Ksir, 1999). Citing
nationwide abuse and the potential health problems ofMDMA, the Drug Enforcement
Agency (DEA) established MDMA a Schedule I controlled substance in 1988 (Lawn,
1988). Despite increased public awareness ofthe health risks associated with MDMA, its
use has continued to rise in recent years, particularly among young people.
MDMA users have consistently reported the subjective effects ofthis substance to
include elevated mood, feelings ofcloseness and intimacy, increased empathy,
insightfulness, mild alterations in perception, accelerated thinking, jaw clenching, and
appetite suppression (Greer & Tolbert, 1986; Grinspoon & Bakalar, 1986; Peroutka,
Newman, & Harris, 1988). MDMA has been ofgreat interest to behavioral
pharmacologists due to its unique profile ofsubjective effects.
Cocaine

Cocaine is an alkaloid obtained from the leaves ofthe coca plant (Vetulani, 2001).
Coca leaves have a long history ofuse by civilizations in the southern hemisphere (Das,
1993; Johanson & Fischman, 1989; Vetulani, 2001). There is evidence that coca leaves
were used in religious ceremonies, as medicine, and to relieve the pain ofhunger
(Johanson & Fischman, 1989). It was not until after the process ofchemically isolating
cocaine from the coca leaf in the 19th century was developed that the implications of
cocaine as a powerful psychostimulant became apparent in the western hemisphere
(Johanson & Fischman, 1989). The purification ofcocaine from its naturally occurring
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plant form is a multi step process. In this process, the intermediate precursor cocaine
sulfate is extracted by washing crushed coca leaves in sulfuric acid or an aromatic
solvent. Cocaine-sulfate is then transformed into cocaine-hydrochloride, a water soluble
white powder. Cocaine-HCl can be administered by snorting or by dissolving in water
and then injecting or drinking the solution. The snorting or injection of cocaine produces
rapid psychostimulant and euphoric effects.
Neuropharmacology ofPsychostimulants
The pharmacological classification of psychostimulants includes a large variety of
compounds, including but not limited to cocaine and t�e amphetamines. In general, the
actions of these compounds fall under the psychomotor stimulant theory of addiction
(Wise & Bozarth, 1987). The psychomotor stimulant theory of addiction is heavily based
on the principles of Skinnerian operant reinforcement. Wise and Bozarth (1987) state;
"The crux of the theory is that the reinforcing effects of drugs, and thus their addiction
liability can be predicted from their ability to induce psychomotor activation" (p. 474). In
advancing beyond the standard Skinnerian approach of considering psychostimulants as
environmental variables, the psychostimulant theory of addiction examines the activation
of dopaminergic pathways and its relevance to forward locomotion (Wise & Bozarth,
1987).
The psychostimulants, amphetamine and cocaine, have been indicated in the
activation of brain reward circuitry and in particular activation of dopamine pathways in
the nucleus accumbens (Wise & Bozarth, 1984). Furthermore, the psychostimulants
cocaine and the amphetamines increase catecholamine levels in the extracellular fluid
space (Bozarth, 1986).
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Nucleus accumbens dopamine has been implicated in the study of motivation and
reward (Salamone, 1996; Salamone, Correa, Mingote, & Weber, 2003; Sokolowski,
Conlan, & Salamone, 1998). It is well documented that most drugs of abuse, including
cocaine, ethanol (Doyon et al., 2003; Mcdowell & Kleber, 1994; Yan, 1999) and
MDMA (Bankson & Yamamoto, 2004; Hser, Huang, Chou, Teruya, & Anglin, 2003;
Koch & Galloway, 1997), increase extracellular dopamine (DA) in the nucleus
accumbens (NAc). Acute administration of MDMA increases the release of both DA and
5-HT in awake-behaving rats (Gough, Ali, Slikker, & Holson, 1991; Hiramatsu & Cho,
1990; Kankaanpaa, Meririnne, Lillsunde, & Seppala, 1998; Yamamoto & Spanos, 1988),
and NAc DA release may be modulated by 5-HT (Filip & Cunningham, 2002; Koch &
Galloway, 1997). Recent studies have shown that MDMA acts at nerve terminals to
modulate release and re-uptake mechanisms of DA and 5-HT (Bankson & Yamamoto,
2004).
Cocaine exerts its actions primarily through blocking DA re-uptake in the central
nervous system. It is well documented that cocaine increases extracellular DA levels in
the nucleus accumbens shell (David, Zahniser, Hoffer, & Gerhardt, 1998). Previous
microdialysis studies have shown that both systemic and local injections of cocaine
increase synaptic 5-HT in the NAc (Teneud, Baptista, Murzi, Hoebel, & Hernandez,
1996). Serotonin and DA interactions on open-field and stereotypical behaviors in rats
following cocaine administration, and the functional importance of increased monoamine
release on behavioral activation have also been established (Broderick & Phelix, 1997).
At the present time, there are no published microdialysis studies on the effects of acute
MOMA/cocaine combinations.
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Rationale for Current Study
It is of great importance to closely approximate human drug use when developing
an animal testing model of drug abuse. The current study simultaneously examined
locomotor activity and neurochemical changes using in vivo microdialysis sampling
techniques to investigate the combined effects of MDMA and cocaine. The locomotor
activity (LMA) testing paradigm is based upon the activation of brain mechanisms
associated with movement. Example behaviors are increased exploratory behavior and
rearing. Due to the association of motor system activation with drugs that produce
reward, the locomotor activity test is often used as a preliminary assessment prior to more
extensive investigations of the behavioral effects of drugs. In vivo microdialysis and High
Performance Liquid Chromatography (HPLC) are commonly used to analyze and
quantify extracellular levels of neurotransmitters in the behaving organism. The analysis
of drug-induced changes in neurotransmitter levels combined with measures of LMA
offers a valuable strategy to assess simultaneously the neurochemical and behavioral
actions of drugs. With respect to drugs of abuse, it is of particular interest to examine the
release of monoamines in the mesocorticolimbic system. Two factors that are highly
related when examining the abuse potential of a drug are behavioral activation and the
release of dopamine in the nucleus accumbens. By using both LMA and microdialysis,
the present study investigated behavioral and neurochemical effects of acute MDMA
cocaine combinations.
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METHOD
Animals
Eighty-four male Sprague-Dawley rats served as subjects (Sasco, Portage, Ml).
Each rat weighed approximately 500 g at the start ofthe experiment. All rats were
individually housed with standard rat chow and water available ad libitum. Rats were
maintained on a 12L: 12D cycle (lights on at 0700h/lights off at 1900 h),at a constant
temperature (20 ± 2° C) and humidity (50 ± 5%). Animals were allowed to recover for
four days prior to testing. Six animals were eliminated from the study due to surgical
complications or problems related to microdialysate sample volume. All procedures were
approved by Western Michigan University's Institutional Animal Care and Use
Committee. In accordance with university policy, all efforts were made to minimize pain
and distress and the number ofanimals used.
Surgical Procedures
Rats were injected with 1.0 mg/kg atropine-sulfate (Calbiochem, San Diego, CA)
15 min. prior to being anesthetized with sodium pentobarbital 51.0 mg/kg (Sigma
Aldrich, St. Louis, MO). Animals were then placed in a Kopfsmall animal stereotaxic
device (David Kopflnstruments, Tujunga, CA) and maintained at 37.5° C using a
Gaymar T/PUMP heat therapy pump (Gaymar Industries Inc, Orchard Park, NY).
Removable guide cannulae (Bioanalytical Systems Inc, West Lafayette, IN) were
stereotaxically implanted in the nucleus accumbens (AP+ 1.70, ML -1.50, DV -6.20)
with the incisor bar adjusted to achieve the flat skull position (Paxinos and Watson,
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1998). Guide cannula were secured in place with three small jewelers screws
(Bioanalytical Systems Inc, West Lafayette, IN) and dental cement (PERM, Hygenic
Corp, Akron, OH).
Behavioral Procedures

Locomotor activity assessment and in vivo microdialysis procedures were
conducted in six identical Plexiglas chambers (16"1 x 16"w x 16"h) equipped with a
Versamax® Activity Monitoring System (Accuscan Instruments Inc., Columbus, OH).
All locomotor data were collected in 30 minute intervals that coincided with
microdialysis sample collection times.
Microdialysis Procedures

BAS BR-2 microdialysis probes (Bioanalytical Systems Inc, West Lafayette, IN)
were flushed with artificial cerebral spinal fluid (aCSF) ( 147.2 mM NaCl, 1.2 mM
CaCh, 2.7 mM KCl, 1.0 mM MgCh ) at a flow rate of 0.5 µI/min 12 hours prior to
calibration using BAS BEE syringe pump (Bioanalytical Systems Inc, West Lafayette,
IN). At 0600h probes were placed in a calibration solution ( 1.5 µm DOPAC , 15 nM DA,
760 nM HVA, 300 nM 5-HIAA, 15 nM 5-HT) at a flow rate of 1.5 µI/min, a 30 minute
calibration sample was collected. At 0700 - 0800h microdialysis probes were inserted
into the guide cannulae and the rats were tethered to an Instech fluid swivel (Plymouth
Meeting PA) attached to a counter-balanced arm and placed in the locomotor activity
chambers. Microdialysis flow rates were maintained at 1.5 µ1/min for the entire
experiment. Following insertion, the probes were allowed to equilibrate for three hours
prior to testing. At approximatelyl 100 h, microdialysis sample collection began. Samples
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were collected at 30 minute intervals and immediately flash frozen and stored in a -80 ° C
freezer until HPLC-EC analysis. The sampling regimen consisted of six 30 minute
baseline samples, one 30 minute vehicle sample, one 30 minute drug injection sample,
and five post injection 30 minute samples.
Histology
At the conclusion of the microdialysis procedure, rats were euthanized by injection
of a solution containing sodium pentobarbital (50 mg/kg) dissolved in a 60% ethanol and
then perfused at a constant pressure of 300 mm/hg with a 10% sucrose solution followed
by a 10% formalin solution using a Perfusion One pressurized perfusion system
(myNeuroLab, St Louis, MO). The microdialysis guides were removed after the
perfusion and the brains were removed from the skulls and stored in 10% formalin. A
Vibratome 1500 sectioning system (Ted Pella Inc, Redding, CA) was used to slice
coronal sections at a thickness of 70 µm. Coronal sections were mounted on microscope
slides and histological placement was confirmed. All probe placements were within the
nucleus accumbens target.
HPLC-EC
Dopamine was detected by reverse phase high performance liquid
chromatography coupled to electrochemical detection. The HPLC-EC system consisted
of an ESA Coulochem II Model 5200 detector, ESA 582 solvent delivery module, ESA
540 autosampler and PC running ESA 501 chromatography software, MD-150/RP-C18
column (particle size 3µm, 3.0 x 150 mm i.d.) and a model 5014 analytical cell (ESA,
Chelmsford, MA). The detector settings were: guard cell 350 mv , CHI: -175 mv and
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CH2: 250 mv, all filter settings were set to 5 sec. A commercially prepared mobile phase,
MD-TM (ESA, Chemlsford, MA) was used consisting of75 mM sodium dihydrogen
phosphate monohydrate, 1.7nm 1-octanesulfonic acid, 100 µ1/L triethyllamine, 25 µm
EDTA, 10% acetonitrile, and adjusted to a pH = 3.0 with phosphoric acid.
Drugs
Cocaine-hydrochloride and 3,4-Methylenedioxymethamphetamine (MDMA)
were obtained from the National Institute on Drug Abuse (Rockville, MD). Sodium
pentobarbital was purchased from Sigma-Aldrich (St. Louis, MO). Atropine sulfate was
purchased from Calbiochem (San Diego, CA). All drugs were dissolved in 0.9% sterile
saline and administered by intraperitoneal injection.
Statistical Analysis

The dependent measures of interest in this study included distance traveled (cm)
and dopamine concentrations during each 30 minute sampling period. These data were
graphed over the 13 sampling periods, which included six baseline samples, one sample
following the vehicle injection, and six samples following the drug injection. For
dopamine concentrations, averages were calculated from the baseline samples and data
points were expressed as a percentage of the baseline average. Analysis of both
locomotor activity and dopamine concentrations was performed by calculating individual
regression line equations for time periods 8 to 13 for each individual subject. The slopes
of the lines were grouped according to drug treatment condition. The slope of the
regression lines for treatment groups based on the LOG of dopamine concentrations were
compared using a One-Way ANOVA and Fisher-Hayter pairwise comparisons were
calculated for treatment effects.
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RESULTS
Figure 1 represents the total distance traveled during each 30 minute sampling
period. Note that drug injections were administered at the beginning ofthe eighth
sampling period. Both doses ofcocaine produced significant increases in locomotor
activity. In comparison, MOMA produced only moderate increases in locomotor activity.
The combined effects ofeither MOMA dose with 10 mg/kg cocaine were similar to the
effects ofthis dose ofcocaine when administered alone. However, the combined
administration of20 mg/kg cocaine and 3.0 mg/kg MOMA produced greater locomotor
activity compared to either dose alone.
Locomotor Activity
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Figure 1. Locomotor Activity

The slope ofthe regression lines (see Figure 2) for treatment groups based on the
LOG ofdistance traveled (cm) were compared by using a One-Way ANOVA. A
significant drug effect was obtained (F(7, 70) = 4.54, p<.01). Fisher-Hayter pairwise
comparisons were calculated for treatment effects and qFH exceeded the critical value
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(q.os,Jt- , N-J) for [MDMA 1.5 vs. MDMA 1.5 + COC 10.0], and [MDMA 1.5 vs. MDMA
3.0 + coc 20.0].
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Figure 2. Regression Lines Log ofLocomotor Activity
Figure 3 shows extracellular dopamine (DA) levels in the nucleus accumbens
(NAc) represented as a percentage ofthe average baseline concentration for each 30
minute sampling period. When administered alone, cocaine increased NAc DA levels to
265% or 450% ofbaseline following a dose of 10 or 20 mg/kg, respectively. MDMA
increased NAc DA levels to 155% or 194 % following 1.5 or 3.0 mg/kg, respectively.
When administered in combination with 1.5 mg/kg MDMA, 10 mg/kg cocaine increased
NAc DA levels by 370% and cocaine 20 mg/kg increased these levels by 532%. When
administered in combination with 3.0 mg/kg MDMA, 10 mg/kg cocaine increased NAc
DA levels by 316% and cocaine 20 mg/kg increased these levels by 700%. Thus, the
combined actions ofMDMA and cocaine appeared to increase NAc DA levels to a
greater extent than either drug alone.
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The slope of the regression lines (see figure 4) for treatment groups based on the
LOG of dopamine concentrations were compared by using a One-Way ANOVA. A
significant drug effect was obtained F(7, 64) = 4.90, p<.01 Fisher-Hayter pairwise
comparisons were calculated for treatment effects. qFH exceeded the critical value (q_os,J1, N-J)

for [MDMA 3.0 vs. MDMA 3.0 + COC 20.0], [MDMA 3.0 vs MDMA 3.0 + COC

10.0], and [MDMA 1.5 vs. MDMA 3.0 + COC 20.0]. These results are indicative of
cocaine's actions to produce a dose-dependent temporal and quantal augmentation of
extracellular dopamine elicited by injection of MDMA 3.0 mg/kg.
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DISCUSSION
Cocaine and MDMA produced the anticipated increase in extracellular NAc DA
levels and locomotor activity resulting from activation ofthe mesocorticolimbic system
(Bozarth, 1986; Bozarth & Wise, 1986). In concordance with the literature, MDMA
produced locomotor system activation and dopamine efflux to a lesser extent than
cocaine (Koch & Galloway, 1997). With respect to a combinatorial effect ofMDMA and
cocaine, MDMA 3.0 mg/kg co-injected with cocaine 20 mg/kg produced dopamine levels
and locomotor activity greater than that ofeither drug alone. These results are indicative
ofa possible MDMA/cocaine synergistic effect which is dose dependent.
The individual effects ofcocaine and MDMA on extracellular dopamine efflux
are well documented. Cocaine increases dopamine efflux in the nucleus accumbens shell
(Morgan, Horan, Dewey, & Ashby, 1997; Morgan et al., 1997; Shimada, Yamaguchi, &
Yanagita, 1996) (Bradberry, 1994, 2002). MDMA has also been demonstrated to enhance
dopamine transmission (Cadoni et al., 2005; Green, Meehan, Elliott, O'Shea, & Colado,
2003; Koch & Galloway, 1997), although the mechanisms related to the efflux of
extracellular dopamine levels differ. It is important to distinguish the action ofcocaine
from the action ofamphetamine-analogs such as MDMA. Cocaine's action ofblocking
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monoamine transporters generates an increase in extracellular dopamine, whereas
amphetamine analogs reverse monoamine transporter activity and in turn increase
dopamine efflux (Metzger, Hanson, Gibb, & Fleckenstein, 1998). It is hypothesized that
MDMA may affect dopamine release by several different mechanisms; (1) by producing
action analogous to amphetamine on dopamine terminals (Cadoni et al., 2005) (2) and
releasing serotonin by acting on 5-HT2 receptors (Bradberry, 1994; Cadoni et al., 2005;
Koch & Galloway, 1997).
The neurobehavioral actions of MDMA and cocaine, when co-administered, have
not been thoroughly investigated. The results of the current study bear some similarity to
findings reported by Morgan et al. (1997) who administered cocaine to rats four hours
following the administration of the cocaine analog RTI-55. RTI-55 has been
demonstrated to have a high binding affinity for the dopamine transporter and the
serotonin transporter. Our results are consistent with those of Morgan and colleagues
(1997), who demonstrated an increase in NAc dopamine levels of 458% over basal levels
following 20 mg/kg cocaine and a 758% increase in dopamine levels following the
administration of both RTI-55 and cocaine. In addition, the RTI/cocaine data parallel our
findings with respect to an augmented temporal duration of the drug combinations on
extracellula NAc dopamine levels. Given the results of Morgan et al (1997) it is
hypothesized that MDMA may augment the effects of cocaine via dopamine transporters.
These results have important implications for future lines of research. Future
research should include the investigation of the appetitive and aversive properties of
MDMA/cocaine combinations. Although these combinations produce increases in
extracellular dopamine, which is highly relevant in relation to reward mechanisms,
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excessive dopamine release may induce a psychological state similar to a drug-induced
amphetamine psychosis, which in tum may be experienced as an aversive condition. To
examine the aversive and appetitive effects of these combinations, the conditioned place
preference paradigm may be employed. To assess the abuse potential of these drug
combinations in animal models, a self-administration ·study could be conducted to
examine whether these combinations will be readily administered and if the rate of
administration is greater for the combination compared to either drug alone. Further
neurochemical investigations ought to be conducted simultaneously with behavioral
experiments to assess the relationship between dopamine release and behavioral effects
of MDMA/cocaine combinations. In addition to the aforementioned studies,
immunohistochemical investigations of the dopamine transporter and tyrosine
hydroxylase activity could be examined. These neurochemical and behavioral studies
may also be extended to examine the chronic effects of combined MDMA and cocaine
administration with respect to their possible neurotoxic consequences.
These preclinical data may generalize to the population of polydrug abusers who
frequently use MDMA in conjunction with other drugs of abuse. The preclinical data
demonstrated an increased effect of cocaine's action on dopamine efflux. This increase in
extracellular dopamine may augment the subjective feeling of euphoria that humans
experience in association with psychostimulant use. MDMA may also extend the
temporal effects of psychostimulant actions in humans, causing a prolonged subjective
euphoric effect. The increase in intensity and temporal elongation of drug action may
contribute to the abuse potential of polydrug use.
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CONCLUSION
Recent reports ofhuman polydrug abuse have demonstrated the popularity of
MDMA use in conjunction with cocaine (Chinet, Stephan, Zobel, & Halfon, 2007;
Marsden et al., 2006) MDMA and cocaine are psychostimulants that individually
produce forward locomotion and elevations in extracellular dopamine. In combination,
these drugs produce a significant increase in extracellular dopamine levels and locomotor
activity greater than either drug alone. The relevant importance ofinvestigating the
neurobehavioral effects ofthis particular drug combination is becoming readily apparent.
Further study ofthe neurochemical, neurobehavioral, and neurotoxic actions of
MDMA/cocaine combinations is warranted.
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